Key result
Flow cytometry accurately assesses clopidogrel response in thrombocytopenia using a <26% reactivity cutoff.
Why the study?
Thrombocytopenia complicates antiplatelet therapy in cardiovascular patients, and accurate methods to measure platelet reactivity during DAPT in these patients are needed.
Does a flow cytometry-based method provide a more accurate assessment of platelet reactivity compared to impedance aggregometry in thrombocytopenic patients on DAPT after PCI?
Cross-Sectional (n=54)
No
Does a flow cytometry-based method provide a more accurate assessment of platelet reactivity compared to impedance aggregometry in thrombocytopenic patients on DAPT after PCI?
Flow cytometry may be more accurate than impedance aggregometry for evaluating clopidogrel responsiveness in thrombocytopenic patients after PCI.
Answers are grounded in this paper and cite their sources.
Supports flow cytometry for clopidogrel assessment in thrombocytopenic DAPT patients; hypothesis-generating and should not yet change practice.
BACKGROUND: Thrombocytopenia remains a significant problem in patients with cardiovascular disease (CVD) due to the indispensable use of antiplatelet therapy. OBJECTIVES: The aim of this study was to establish a novel flow cytometry (FC)-based method for measuring platelet reactivity during dual antiplatelet therapy (DAPT) and to compare it with impedance aggregometry (IA) in thrombocytopenic patients undergoing percutaneous coronary intervention (PCI). MATERIAL AND METHODS: This prospective cross-sectional study included 30 patients with thrombocytopenia. Platelet aggregation was assessed using IA and FC. RESULTS: A similar response to arachidonic acid (AA), reflecting the effect of acetylsalicylic acid (ASA), was observed in both groups. Responses to thrombin receptor agonist peptide (TRAP) and adenosine diphosphate (ADP), measured with aggregometry, were significantly higher in thrombocytopenic patients than in patients with normal platelet counts. When the FC method was used, the response to AA was significantly higher in thrombocytopenic patients. The optimal cut-off value for the FC method to define adequate platelet reactivity inhibition with clopidogrel in thrombocytopenic patients was <25.7%. CONCLUSIONS: In patients with thrombocytopenia, IA is useful for assessing ASA response, whereas the presented FC method may be more accurate for evaluating response to clopidogrel.
No takes yet. Share an insight, caveat, or question.
Wilczewska et al. (2026) conducted a cross-sectional in Thrombocytopenia in patients on dual antiplatelet therapy after percutaneous coronary intervention (n=54). Thrombocytopenia vs. Normal platelet count was evaluated on Clopidogrel response assessed by flow cytometry (ADP-FLC median) (p=0.653). In thrombocytopenic patients on dual antiplatelet therapy, flow cytometry provided a count-independent assessment of clopidogrel response with an optimal cut-off of <25.7% for adequate inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: